Jazz Pharmaceuticals vs Perrigo
Jazz Pharmaceuticals reported revenue of $4.3 billion in fiscal 2025, about the same as Perrigo's $4.3 billion in fiscal 2025. Jazz Pharmaceuticals' revenue grew 4.9% in its latest year, and Perrigo's fell 2.8%. Jazz Pharmaceuticals had an operating margin of -10.1%, against -26.4% at Perrigo. Free cash flow was $1.3 billion at Jazz Pharmaceuticals and $145 million at Perrigo.
Side by side
| Jazz Pharmaceuticals | Perrigo | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $4.3B | $4.3B |
| Revenue growth | 4.9% | −2.8% |
| Revenue growth a year, last 5 years | 12.5% | 0.8% |
| Gross margin | — | 35.1% |
| Operating margin | −10.1% | −26.4% |
| Net margin | −8.3% | −33.5% |
| Free cash flow | $1.3B | $145M |
| Free cash flow margin | 30.4% | 3.4% |
| Return on capital | −4.2% | −13.2% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $125M | $159M |
| Change in diluted share count | −7.6% | 0.8% |
| Last close | $205.70 | $15.82 |
| P/E at the last close | 14.1× | — |
| Insider trades, last 12 months | sold $68.0 million | bought $106,350, sold $0 |
| Piotroski F-score | 4 of 8 | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Jazz PharmaceuticalsPerrigo
Operating margin
Percent of revenue
Jazz PharmaceuticalsPerrigo
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Jazz PharmaceuticalsPerrigo
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Jazz Pharmaceuticals and Perrigo pages.